Idorsia Pharmaceuticals Ltd

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Marilda Lisboa

Claney Lebev Pereira

Sharavathi Guddehalli Parameswarappa

Bopanna Monnanda

Arne Von Bonin

Peter H Seeberger

Naeem Khan

Madhu Emmadi

Sylvia Oestreich

Christopher Martin

Jessica Przygodda

Chakkumkal Anish

Benjamin Schumann

Lennart Lykke

Daniel Knopp

Fei-Fei Xu

Adam Calow

Paulina Kaplonek

Petra Menova

The present invention relates to a synthetic saccharide of general formulate (I) that is related toPS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againstbacteria.

Stable vaccine against

The present invention relates to a synthetic saccharide of general formula (I) that is related toserotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistantST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againstbacteria.

Vaccine against klebsiella pneumoniae

Vaccine against

The present invention relates to immunogenic compositions comprising a conjugate of a saccharide fromserotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides fromserotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRMcarrier protein, or a mixture consisting of capsular polysaccharides fromserotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides fromserotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide fromserotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide fromserotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by

Pneumococcal polysaccharide-protein conjugate composition

The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit ofserotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with, and more specifically against diseases associated withserotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies againstbacteria. 

Vaccines againstserotype 5

Growing community of inventors

Berlin, Germany

Marilda Lisboa